The RECAP2 Study: Midazolam and Psilocybin

This triple-blind, randomised, placebo-controlled trial (n=60) will study the role of neuroplasticity in the behavioural effects of psilocybin in individuals with mild declines in emotional wellbeing. Participants will receive one of four medication combinations, involving either 25 mg or 1 mg of psilocybin alongside intravenous (IV) midazolam or IV saline.

The study, sponsored by the University of Wisconsin, Madison, aims to assess whether psilocybin-induced neuroplasticity contributes to improved wellbeing.

Participants will undergo MRI scans, complete questionnaires, and receive transcranial magnetic stimulation (TMS) and EEG assessments. The primary outcomes include changes in cognitive flexibility, wellbeing, and experiential avoidance, with secondary measures evaluating psychological flexibility, emotional breakthroughs, and neural excitability. The trial is expected to begin in February 2025 and conclude in November 2027.

Topic Neuroscience Healthy Subjects
Compound Psilocybin
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 February 2025
End date 01 November 2027
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 60
Sex All
Age 18- 70
Therapy No

Trial Details

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: -Receive one of four possible combinations of medications -Undergo an MRI -Complete questionnaires -Undergo transcranial magnetic stimulation (TMS) and EEG

Trial Number NCT06692192

Sponsors & Collaborators

University of Wisconsin-Madison
The Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was launched at the University of Wisconsin-Madison in 2021.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.